InnovaxNews Articles
Continued: IVI and Innovax Launch Efforts to Make World’s First Hepatitis E Vaccine Available for Global Public Health
Xiamen,China – On first and second day of November of this year, the final meeting for assessment of Hepatitis E vaccine was held smoothly at INNOVAX. The outcome from the assessment was
EV-71Scientific Articles
Immunodominant IgM and IgG Epitopes Recognized by Antibodies Induced in Enterovirus A71-Associated Hand, Foot and Mouth Disease Patients
Abstract – Enterovirus A71 (EV-A71) is one of the main causative agents of hand, foot and mouth disease (HFMD). Unlike other enteroviruses that cause HFMD, EV-A71 is more frequently
InnovaxNews Articles
Mr. Steven Gao Elected as the DCVMN Executive Committee Member for the Fourth Consecutive Time
The general manager of INNOVAX – Mr. Steven Gao was elected to the new executive committee in the DCVMN Annual Meeting in Buenos Aires, Argentina, 26 Oct 2016. A total of seven executive
InnovaxNews Articles
IVI and Innovax Launch Efforts to Make World’s First Hepatitis E Vaccine Available for Global Public Health
Xiamen, China – The International Vaccine Institute (IVI) and Xiamen Innovax Biotech Co., Ltd. (Innovax) have entered a collaboration to make Hecolin?, the world’s first Hepatitis E vaccine,
Hepatitis EScientific Articles
Long-Term Efficacy of a Hepatitis E Vaccine
Hepatitis E virus (HEV) is a common cause of acute hepatitis worldwide.1,2 HEV infection occurs in two distinct epidemiologic patterns.3 The most common pattern is waterborne infection, which is
InnovaxNews Articles
First Genital Warts Vaccine in China Starts the Phase I Clinical Trial
The Phase I clinical trial of the first genital warts vaccine (HPV 6/11 vaccine) in China is recently initiated in the Liuzhou city of Guangxi province, March 26, 2015. This HPV6/11 vaccine, with
HecolinNews Articles
WHO Strategic Advisory Group of Experts on Immunization Assessed Hecolin® as a Promising Vaccine
In the meeting of Strategic Advisory Group of Experts (SAGE) on immunization on 21–23 October 2014 in Geneva, Switzerland, the SAGE Hepatitis E Working Group report to SAGE information on the